CA2417897C - Heterocycles bicycliques, compositions pharmaceutiques comprenant ces composes, leur utilisation et procedes permettant de les produire - Google Patents

Heterocycles bicycliques, compositions pharmaceutiques comprenant ces composes, leur utilisation et procedes permettant de les produire Download PDF

Info

Publication number
CA2417897C
CA2417897C CA002417897A CA2417897A CA2417897C CA 2417897 C CA2417897 C CA 2417897C CA 002417897 A CA002417897 A CA 002417897A CA 2417897 A CA2417897 A CA 2417897A CA 2417897 C CA2417897 C CA 2417897C
Authority
CA
Canada
Prior art keywords
amino
quinazoline
oxo
chloro
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002417897A
Other languages
English (en)
Other versions
CA2417897A1 (fr
Inventor
Frank Himmelsbach
Elke Langkopf
Birgit Jung
Stefan Blech
Flavio Solca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2417897A1 publication Critical patent/CA2417897A1/fr
Application granted granted Critical
Publication of CA2417897C publication Critical patent/CA2417897C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

L'invention concerne des hétérocycles bicycliques de formule générale (I) dans laquelle Ra,Rb et n ont la signification mentionnée dans la revendication 1, leurs tautomères, leurs stéréoisomères et leurs sels, notamment leurs sels physiologiquement tolérables avec des acides ou des bases inorganiques ou organiques, qui présentent des propriétés pharmacologiques intéressantes, en particulier un effet inhibiteur sur la transduction de signaux induite par tyrosine-kynases. L'invention concerne en outre l'utilisation desdits hétérocycles bicycliques pour traiter des affections, en particulier des affections tumorales, des affections des poumons et des voies respiratoires, ainsi que leur mode de production.
CA002417897A 2000-08-26 2001-08-18 Heterocycles bicycliques, compositions pharmaceutiques comprenant ces composes, leur utilisation et procedes permettant de les produire Expired - Fee Related CA2417897C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10042058A DE10042058A1 (de) 2000-08-26 2000-08-26 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058.3 2000-08-26
PCT/EP2001/009532 WO2002018351A1 (fr) 2000-08-26 2001-08-18 Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire

Publications (2)

Publication Number Publication Date
CA2417897A1 CA2417897A1 (fr) 2003-01-30
CA2417897C true CA2417897C (fr) 2009-03-31

Family

ID=7653945

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002417897A Expired - Fee Related CA2417897C (fr) 2000-08-26 2001-08-18 Heterocycles bicycliques, compositions pharmaceutiques comprenant ces composes, leur utilisation et procedes permettant de les produire

Country Status (31)

Country Link
EP (1) EP1315705A1 (fr)
JP (1) JP4834282B2 (fr)
KR (1) KR100862873B1 (fr)
CN (1) CN100404517C (fr)
AR (1) AR033562A1 (fr)
AU (2) AU8769401A (fr)
BG (1) BG107559A (fr)
BR (1) BR0113519A (fr)
CA (1) CA2417897C (fr)
CZ (1) CZ302567B6 (fr)
DE (1) DE10042058A1 (fr)
EA (1) EA005679B1 (fr)
EC (1) ECSP034464A (fr)
EE (1) EE05269B1 (fr)
HK (1) HK1057557A1 (fr)
HR (1) HRP20030138A2 (fr)
HU (1) HUP0300819A3 (fr)
IL (2) IL154602A0 (fr)
ME (1) MEP58708A (fr)
MX (1) MXPA03001483A (fr)
MY (1) MY126132A (fr)
NO (1) NO324866B1 (fr)
NZ (1) NZ524668A (fr)
PL (1) PL360248A1 (fr)
RS (1) RS52279B (fr)
SK (1) SK287747B6 (fr)
TW (1) TWI294422B (fr)
UA (1) UA73004C2 (fr)
UY (1) UY26903A1 (fr)
WO (1) WO2002018351A1 (fr)
ZA (1) ZA200300991B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04748B1 (et) 1999-06-21 2006-12-15 Boehringer Ingelheim Pharma Kg Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10214412A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP2277867B1 (fr) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Composés, compositions pharmaceutiques les contenants et leur utilisation pour traiter le cancer
DE10326186A1 (de) * 2003-06-06 2004-12-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
DK2392564T3 (da) 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
DE10345875A1 (de) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10350717A1 (de) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
TW200640904A (en) 2005-02-26 2006-12-01 Astrazeneca Ab Quinazoline derivatives
KR100673775B1 (ko) * 2005-04-08 2007-01-24 엘지전자 주식회사 냉장고용 홈바
EP1919900A2 (fr) * 2005-08-22 2008-05-14 Boehringer Ingelheim International Gmbh Heterocycles bicycliques, produits pharmaceutiques contenant ces composes, leur utilisation et procede pour les preparer
WO2007054550A1 (fr) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Derives de quinazoline pour le traitement des affections cancereuses
WO2007101782A1 (fr) * 2006-03-09 2007-09-13 Boehringer Ingelheim International Gmbh Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
DK2068880T3 (da) 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
EP1921070A1 (fr) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
WO2008095847A1 (fr) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation
WO2009098061A1 (fr) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour les produire
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
KR101645112B1 (ko) 2013-03-06 2016-08-02 아스트라제네카 아베 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
DK3126354T3 (da) * 2014-04-04 2020-03-09 H Lundbeck As Halogenerede quinazolin-thf-aminer som pde1-inhibitorer
US20170176028A1 (en) 2015-12-18 2017-06-22 Lg Electronics Inc. Air conditioner
AU2017363199B2 (en) 2016-11-17 2023-08-17 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
CN112321814B (zh) * 2020-12-30 2021-03-23 广州初曲科技有限公司 一种吉非替尼艾地苯醌轭合物的制备及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) * 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69709319T2 (de) * 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
DE69710712T3 (de) * 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CN100404517C (zh) 2008-07-23
UA73004C2 (uk) 2005-05-16
NO20030870L (no) 2003-02-25
SK2312003A3 (en) 2003-10-07
IL154602A (en) 2008-07-08
NO20030870D0 (no) 2003-02-25
NZ524668A (en) 2006-06-30
PL360248A1 (en) 2004-09-06
TWI294422B (en) 2008-03-11
EA200300219A1 (ru) 2003-08-28
NO324866B1 (no) 2007-12-17
KR20030024914A (ko) 2003-03-26
CN1449390A (zh) 2003-10-15
MXPA03001483A (es) 2003-06-06
WO2002018351A1 (fr) 2002-03-07
HUP0300819A2 (hu) 2003-09-29
EE05269B1 (et) 2010-02-15
BG107559A (bg) 2003-10-31
UY26903A1 (es) 2002-03-22
IL154602A0 (en) 2003-09-17
MY126132A (en) 2006-09-29
DE10042058A1 (de) 2002-03-07
EA005679B1 (ru) 2005-04-28
AU2001287694B2 (en) 2007-09-06
EP1315705A1 (fr) 2003-06-04
CA2417897A1 (fr) 2003-01-30
HUP0300819A3 (en) 2008-03-28
CZ302567B6 (cs) 2011-07-13
EE200300077A (et) 2004-12-15
JP2004507529A (ja) 2004-03-11
ZA200300991B (en) 2004-04-16
YU14003A (sh) 2006-01-16
AU8769401A (en) 2002-03-13
RS52279B (en) 2012-10-31
MEP58708A (en) 2011-05-10
JP4834282B2 (ja) 2011-12-14
SK287747B6 (sk) 2011-08-04
BR0113519A (pt) 2003-07-01
HRP20030138A2 (en) 2005-04-30
AR033562A1 (es) 2003-12-26
HK1057557A1 (en) 2004-04-08
KR100862873B1 (ko) 2008-10-15
ECSP034464A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
CA2417897C (fr) Heterocycles bicycliques, compositions pharmaceutiques comprenant ces composes, leur utilisation et procedes permettant de les produire
US6656946B2 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
CA2417652C (fr) Heterocycles bicycliques, compositions pharmaceutiques contenant ces composes, leur utilisation et procedes permettant de les produire
DK1731511T3 (en) Bicyclic heterocyclic structures, pharmaceutical compositions containing these compounds, their use and process for their preparation
US6617329B2 (en) Aminoquinazolines and their use as medicaments
US6653305B2 (en) Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6403580B1 (en) Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP1163227B1 (fr) Heterocycles bicycliques, compositions pharmaceutiques contenant ces composes, utilisations et procedes de preparation de ces derniers
US6740651B2 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
CA2417050C (fr) Heterocycliques bicyclique, compositions pharmaceutiques contenant ces composes, leurs utilisations et procedes permettant de les produire
US8586608B2 (en) Quinazoline derivatives and pharmaceutical compositions containing them
CA2432428C (fr) Derives de la quinazoline, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
US20020082270A1 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US20060063752A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
AU2006326157A1 (en) Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
CA2417907A1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
CA2417042A1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
CA2417955A1 (fr) Quinazolines, compositions pharmaceutiques comprenant ces composes, leur utilisation et procedes permettant de les produire

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130820